Darya-Varia Laboratoria Tbk (DVLA) - Total Assets

Latest as of June 2025: Rp2.40 Trillion IDR ≈ $140.52 Million USD

Based on the latest financial reports, Darya-Varia Laboratoria Tbk (DVLA) holds total assets worth Rp2.40 Trillion IDR (≈ $140.52 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See DVLA net asset value for net asset value and shareholders' equity analysis.

Darya-Varia Laboratoria Tbk - Total Assets Trend (2000–2024)

This chart illustrates how Darya-Varia Laboratoria Tbk's total assets have evolved over time, based on quarterly financial data.

Darya-Varia Laboratoria Tbk - Asset Composition Analysis

Current Asset Composition (December 2024)

Darya-Varia Laboratoria Tbk's total assets of Rp2.40 Trillion consist of 70.4% current assets and 29.6% non-current assets.

Asset Category Amount (IDR) % of Total Assets
Cash & Equivalents Rp0.00 16.6%
Accounts Receivable Rp741.93 Billion 34.3%
Inventory Rp398.56 Billion 18.4%
Property, Plant & Equipment Rp472.88 Billion 21.9%
Intangible Assets Rp57.21 Billion 2.7%
Goodwill Rp10.28 Billion 0.5%

Asset Composition Trend (2000–2024)

This chart illustrates how Darya-Varia Laboratoria Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Darya-Varia Laboratoria Tbk.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Darya-Varia Laboratoria Tbk's current assets represent 70.4% of total assets in 2024, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 16.6% of total assets in 2024, up from 3.8% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 28.0% in 2000.
  • Asset Diversification: The largest asset category is accounts receivable at 34.3% of total assets.

Darya-Varia Laboratoria Tbk Competitors by Total Assets

Key competitors of Darya-Varia Laboratoria Tbk based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Darya-Varia Laboratoria Tbk - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.37 2.57 3.25
Quick Ratio 1.75 1.93 2.27
Cash Ratio 0.00 0.00 0.00
Working Capital Rp1.01 Trillion Rp984.12 Billion Rp944.57 Billion

Darya-Varia Laboratoria Tbk - Advanced Valuation Insights

This section examines the relationship between Darya-Varia Laboratoria Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.21
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 5.8%
Total Assets Rp2.16 Trillion
Market Capitalization $105.33 Million USD

Valuation Analysis

Below Book Valuation: The market values Darya-Varia Laboratoria Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Darya-Varia Laboratoria Tbk's assets grew by 5.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Darya-Varia Laboratoria Tbk (2000–2024)

The table below shows the annual total assets of Darya-Varia Laboratoria Tbk from 2000 to 2024.

Year Total Assets Change
2024-12-31 Rp2.16 Trillion
≈ $126.66 Million
+5.85%
2023-12-31 Rp2.04 Trillion
≈ $119.66 Million
+1.64%
2022-12-31 Rp2.01 Trillion
≈ $117.73 Million
-3.68%
2021-12-31 Rp2.09 Trillion
≈ $122.23 Million
+4.99%
2020-12-31 Rp1.99 Trillion
≈ $116.41 Million
+8.57%
2019-12-31 Rp1.83 Trillion
≈ $107.23 Million
+8.74%
2018-12-31 Rp1.68 Trillion
≈ $98.61 Million
+2.56%
2017-12-31 Rp1.64 Trillion
≈ $96.15 Million
+7.15%
2016-12-31 Rp1.53 Trillion
≈ $89.73 Million
+11.27%
2015-12-31 Rp1.38 Trillion
≈ $80.64 Million
+11.33%
2014-12-31 Rp1.24 Trillion
≈ $72.44 Million
+3.88%
2013-12-31 Rp1.19 Trillion
≈ $69.73 Million
+10.73%
2012-12-31 Rp1.07 Trillion
≈ $62.97 Million
+15.77%
2011-12-31 Rp928.29 Billion
≈ $54.39 Million
+8.69%
2010-12-31 Rp854.11 Billion
≈ $50.05 Million
+9.00%
2009-12-31 Rp783.61 Billion
≈ $45.92 Million
+22.89%
2008-12-31 Rp637.66 Billion
≈ $37.36 Million
+13.68%
2007-12-31 Rp560.93 Billion
≈ $32.87 Million
+0.64%
2006-12-31 Rp557.34 Billion
≈ $32.66 Million
+1.22%
2005-12-31 Rp550.63 Billion
≈ $32.26 Million
+27.70%
2004-12-31 Rp431.17 Billion
≈ $25.27 Million
+15.42%
2003-12-31 Rp373.56 Billion
≈ $21.89 Million
+15.68%
2002-12-31 Rp322.92 Billion
≈ $18.92 Million
-15.12%
2001-12-31 Rp380.44 Billion
≈ $22.29 Million
+1.11%
2000-12-31 Rp376.28 Billion
≈ $22.05 Million
--

About Darya-Varia Laboratoria Tbk

JK:DVLA Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$105.33 Million
Rp1.80 Trillion IDR
Market Cap Rank
#18980 Global
#333 in Indonesia
Share Price
Rp1605.00
Change (1 day)
+0.00%
52-Week Range
Rp1580.00 - Rp1710.00
All Time High
Rp2534.71
About

PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company offers prescription products in various areas of cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women hea… Read more